These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 32519066)

  • 1. Biotechnology Approaches for the Treatment of Dyslipidemia.
    Parolini C
    Cardiovasc Drugs Ther; 2021 Feb; 35(1):167-183. PubMed ID: 32519066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-Lowering Agents.
    Hegele RA; Tsimikas S
    Circ Res; 2019 Feb; 124(3):386-404. PubMed ID: 30702996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new dawn for managing dyslipidemias: The era of rna-based therapies.
    Macchi C; Sirtori CR; Corsini A; Santos RD; Watts GF; Ruscica M
    Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moving Targets: Recent Advances in Lipid-Lowering Therapies.
    Larsen LE; Stoekenbroek RM; Kastelein JJP; Holleboom AG
    Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):349-359. PubMed ID: 30676072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective.
    Jia X; Liu J; Mehta A; Ballantyne CM; Virani SS
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1269-1279. PubMed ID: 32997212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.
    Luo F; Das A; Khetarpal SA; Fang Z; Zelniker TA; Rosenson RS; Qamar A
    Trends Cardiovasc Med; 2024 May; 34(4):215-222. PubMed ID: 36746257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Antisense Therapies Targeting Lipoprotein(a).
    Plakogiannis R; Sorbera M; Fischetti B; Chen M
    J Cardiovasc Pharmacol; 2021 Jul; 78(1):e5-e11. PubMed ID: 34232223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
    Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
    Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study.
    Moriarty PM; Roth EM; Karns A; Ye P; Zhao SP; Liao Y; Capuzzi DM; Bays HE; Zhang F; Liu S; Reichman AJ; Brusco OA; Lu G; Lerman S; Duan Z; Guo S; Liu PL; Zhao J; Zhang Y; Li S
    J Clin Lipidol; 2014; 8(6):568-575. PubMed ID: 25499939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
    Kastelein JJ; van der Steeg WA; Holme I; Gaffney M; Cater NB; Barter P; Deedwania P; Olsson AG; Boekholdt SM; Demicco DA; Szarek M; LaRosa JC; Pedersen TR; Grundy SM; ;
    Circulation; 2008 Jun; 117(23):3002-9. PubMed ID: 18519851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
    J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.